Atopic Dermatitis Clinical Trials in Sacramento, California

8 studies are recruiting for atopic dermatitis in Sacramento, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Integrative Skin Science and Research, Sacramento, California

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

2. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

   This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Sacramento, California

   Locations

   105 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06947993 on ClinicalTrials.gov

3. Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

   This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.

   Stage

   Phase 4

   Ages

   12 and older

   Site

   Integrative Skin Science and Research, Sacramento, California

   Run by

   Integrative Skin Science and Research

   See if you can join NCT07560618 on ClinicalTrials.gov

4. A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupil…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Integrative Skin Science and Research /ID# 265108, Sacramento, California

   Locations

   150 in total

   Run by

   AbbVie

   See if you can join NCT06461897 on ClinicalTrials.gov

5. A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

   The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of …

   Stage

   Phase 3

   Ages

   0 to 11

   Site

   Leo Pharma Investigational site, Sacramento, California

   Locations

   72 in total

   Run by

   LEO Pharma

   See if you can join NCT06311682 on ClinicalTrials.gov

6. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   Integrative Skin Science and Research /ID# 264537, Sacramento, California

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov

7. Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   University of California, Davis Health, Department of Dermatology, Sacramento, California

   Locations

   16 in total

   Run by

   Oneness Biotech Co., Ltd.

   See if you can join NCT06397911 on ClinicalTrials.gov

8. A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

   Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with mo…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Physioseq, LLC /ID# 267266, Sacramento, California

   Locations

   2 in total

   Run by

   AbbVie

   See if you can join NCT06524635 on ClinicalTrials.gov